Editas, Beam win bullish views as Cantor launches gene editing coverage

Concept of treatment and adjustment of DNA .


Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), and Beam Therapeutics (NASDAQ:BEAM) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the firm launched its coverage on several gene editing companies.

The analyst Rick Bienkowski sees multiple